全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Ankle-Brachial Index in Systemic Lupus Erythematosus: A Senegalese Case-Control Study

DOI: 10.4236/wjcd.2019.912084, PP. 958-968

Keywords: Systemic Lupus Erythematosus, Subclinical Atherosclerosis, Peripheral Arterial Disease, Ankle-Brachial Index, Africa South of the Sahara

Full-Text   Cite this paper   Add to My Lib

Abstract:

Systemic lupus erythematosus (SLE) is associated with accelerated atherosclerosis and increasing cardiovascular risk which is recognized as a major cause of morbidity and death. Whether subclinical atherosclerosis has been evaluated by several methods, there are very limited data about Ankle-Brachial Index (ABI) in patients with systemic lupus erythematosus. The aim of the present study was to compare this index, between SLE patients and controls. We conducted a case-control study in the Department of Internal Medicine of our institution during the period from August 1, 2017 to December 31, 2018. We included 100 subjects, including 50 SLE patients and 50 control cases. This included 44 women and 6 men in patients with an identical distribution in controls. The mean age was 33.5 ± 11.3 years for cases and 33.3 ± 11.3 years (p-value: 0.93) for controls subjects. There was higher frequency of cardiovascular risk factors such as dyslipidemia (p-value at 0.009), low level of serum HDL-cholesterol (p-value?<0.001), hypertriglyceridemia (p-value at 0.000) and hyperuricemia (p-value at 0.000) in patients with SLE. Overweight/obesity was higher in controls subjects (p-value at 0.028). There was no statistically significant difference in the frequency of diabetes-mellitus, smoking and high blood pressure. The abnormally ABI was recorded in 19 patients with SLE (38%) and 8 controls (16%) with a p-value: 0.01 and odds ratio: 3.22. Eight patients (16%) and four controls (8%) had low ABI without significant difference (p-value: 0.11 but odds-ratio at 2.98). Eleven patients with SLE (22%) and five controls (10%) had high ABI (p-value: 0.05 and odds-ratio: 3.24). In patients with SLE only disease activity (cSLEDAI) at the inclusion of the study was correlated?to abnormal

References

[1]  Felten, R., Dervoric, E., Chasset, F., Gottenberg, J.E., Sibilia, J., Scher, F. and Arnaud, L. (2018) The 2018 Pipeline of Targeted Therapies under Clinical Development for Systemic Lupus Erythematosus: A Systematic Review of Trials. Autoimmunity Reviews, 17, 781-790.
https://doi.org/10.1016/j.autrev.2018.02.011
[2]  Hassan, A.A., Habib, H.M. and Eissa, A.A. (2013) Peripheral Arterial Disease in Patients with Systemic Lupus Erythematosus. International Journal of Rheumatic Diseases, 16, 319-324.
https://doi.org/10.1111/1756-185x.12025
[3]  Croca, S. and Rahman, A. (2017) Atherosclerosis in Systemic Lupus Erythematosus. Best Practice & Research: Clinical Rheumatology, 31, 364-372.
https://doi.org/10.1016/j.berh.2017.09.012
[4]  Freri, M. and Stampfl, H. (2016) Systemic Lupus Erythematosus and Atherosclerosis: Review of the Literature. Autoimmunity Reviews, 15, 16-21.
https://doi.org/10.1016/j.autrev.2015.08.007
[5]  Mayra, G. and Mavragani, C.P. (2017) Cardiovascular Disease in Systemic Lupus Erythematosus: A Comprehensive Update. Journal of Autoimmunity, 82, 1-12.
https://doi.org/10.1016/j.jaut.2017.05.008
[6]  Petri, M.A., Barr, E. and Magder, L.S. (2019) Development of a Systemic Lupus Erythematosus Cardiovascular Risk Equation. Lupus Science & Medicine, 6, e000346.
https://doi.org/10.1136/lupus-2019-000346
[7]  McMahon, M., Skaggs, B., Grossman, J., Wong, W.K. and Sahakian, L. (2019) Comparison of Predicts Atherosclerosis Biomarkers Changes after Initiation of New Treatments in Patients with SLE. Lupus Science & Medicine, 6, e000321.
https://doi.org/10.1136/lupus-2019-000321
[8]  Tziomalos, K., Gkougkourelas, I., Sarantopoulos, A., Bekiari, E., Makri, E., Raptis, N., et al. (2017) Arterial Stiffness and Peripheral Arterial Disease in Patients with Systemic Lupus Erythematosus. Rheumatology International, 37, 293-298.
https://doi.org/10.1007/s00296-016-3610-4
[9]  Yang, D.H., Leong, P.Y., Sia, S.K., Wang, Y.H. and Wei, J.C. (2019) Long-Term Hydroxyxhloroquine Therapy and Risk of Coronary Artery Disease in Patients with Systemic Lupus Erythematosus. Journal of Clinical Medicine, 5, Pii: E796.
https://doi.org/10.3390/jcm8060796
[10]  Mercurio, V., Lobasso, A., Barbieri, L., Parella, P., Ciervo, D., et al. (2019) Inflammatory, Serological and Vascular Determinants of Cardiovascular Disease in Systemic Lupus Erythematosus Patients. International Journal of Molecular Sciences, 20, 2154.
https://doi.org/10.3390/ijms20092154
[11]  June, R.R. and Scalzi, L.V. (2013) Peripheral Vascular Disease in Systemic Lupus Patients. Journal of Clinical Rheumatology, 19, 367-372.
https://doi.org/10.1097/RHU.0000000000000017
[12]  Jung, J., Kim, H., Lee, H.Y. and Suh, C. (2019) Body Mass Index and Glucocorticoid Dose Contribute to Atherosclerosis in Korean Patients with Systemic Lupus Erythematosus. A Prospective 4 Years Follow-Up Study. International Journal of Rheumatic Diseases, 22, 1410-1418.
https://doi.org/10.1111/1756-185X.13588
[13]  Roldan, P.C., Greene, E.R., Qualls, C.R., Sibbitt, W.L. and Roldan, C.A. (2019) Progression of Atherosclerosis versus Arterial Stiffness with Age within and between Arteries in Systemic Lupus Erythematosus. Rheumatology International, 39, 1027-1036.
https://doi.org/10.1007/s00296-019-04267-y
[14]  Aboyans, V., Criqui, M.H., Abraham, P., Allison, M.A., Creager, M.A., Diehm, C., et al. (2012) Measurement and Interpretation of Ankle-Brachial Index. A Scientific Statement from the American Heart Association. Circulation, 126, 2890-2909.
https://doi.org/10.1161/CIR.0b013e318276fbcb
[15]  Hossain, P., Kokkinidis, D.G. and Armstrong, E.J. (2019) How to Assess a Claudication and When to Intervene. Current Cardiology Reports, 21,138.
https://doi.org/10.1007/s11886-019-1227-4
[16]  Hong, J.B., Leonards, C.O., Endres, M., Siegerink, B. and Liman, T.G. (2016) Ankle-Brachial Index and Recurrent Stroke Risk: Meta-Analysis. Stroke, 47, 317-322.
https://doi.org/10.1161/STROKEAHA.115.011321
[17]  Chuang, Y.W., Yu, M.C., Lin, C.L., Yu, T.M., Shu, K.H. and Kao, C.H. (2015) Risk of Peripheral Arterial Occlusive Disease in Patients with Systemic Lupus Erythematosus. Medicine, 94, 1-7.
https://doi.org/10.1097/MD.0000000000002121
[18]  Hochberg, M.C. (1997) Updating the American College of Rheumatology Revised Criteria for the Classification of Systemic Lupus Erythematosus. Arthritis & Rheumatology, 40, 1725.
https://doi.org/10.1002/art.1780400928
[19]  Parodis, I., Emamika, S., Gomez, A., Gunnarson, I., Van Vollenhoven, R.F. and Chatzidioniysiou (2019) Clinical SLEDAI-2K Zero May Be a Pragmatic Outcome Measure in SLE Studies. Expert Opinion on Biological Therapy, 19, 157-168.
https://doi.org/10.1080/14712598.2019.1561856
[20]  Dorner, T. and Furie, R. (2019) Novel Paradigms in Systemic Lupus Erythematosus. The Lancet, 393, 2344-2358.
https://doi.org/10.1016/S0140-6736(19)30546-X
[21]  Cervera, R., Khamashta, M.A., Font, J., Sebastiani, G.D., Gil, A., Lavilla, P., et al. (1993) Systemic Lupus Erythematosus: Clinical and Immunologic Patterns of Disease Expression in a Cohort of 1000 Patients. Medicine, 72, 113-124.
https://doi.org/10.1097/00005792-199303000-00005
[22]  Erdozain, J.G., Villar, I., Nieto, J. and Ruiz-Irastorza (2014) Peripheral Arterial Disease in Systemic Lupus Erythematosus: Prevalence and Risk Factors. The Journal of Rheumatology, 41, 310-317.
https://doi.org/10.3899/jrheum.130817
[23]  Urowitz, M.B., Bookman, A.A., Koehler, B.E., Smythe, H.A. and Ogryzlo, M.A. (1976) The Bimodal Mortality Pattern of Systemic Lupus Erythematosus. The American Journal of Medicine, 60, 221-225.
https://doi.org/10.1016/0002-9343(76)90431-9

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133